Etira to Present Promising Preclinical Data at AACR 2025
Etira announces three abstracts featuring preclinical data on ERX-208 and ERX-315 will be presented at the AACR Annual Meeting 2025 in San Diego. Highlights include ERX-208's breakthrough potential in ovarian cancer, its synergy with FDA-approved therapies, and validation of ERX-315, currently in a Phase 1 trial for liver cancer. “We’re building a strong case for these novel agents as standalone or combination therapies,” said Dr. Ratna Vadlamudi of UT Health San Antonio.
Etira to Present Promising Preclinical Data at AACR 2025